GenesisCare Hurstville Trials

GenesisCare Hurstville	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Joshua, Anthony

MAST, NCT01864096: The Metformin Active Surveillance Trial () Study

Active, not recruiting

408

Canada

Metformin, Metformin hydrochloride, Placebo, Placebo tablet

University Health Network, Toronto

Prostate Cancer

02/24

08/24

CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting

900

Europe, Canada, Japan, US, RoW

Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib

Eli Lilly and Company

Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6

02/24

10/27

DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting

1100

Europe, Canada, US, RoW

Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy

University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium

Prostate Cancer

01/28

07/28

NADOM, NCT05187884: Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Active, not recruiting

RoW

Darovasertib

Anthony Joshua, FRACP, St Vincent's Hospital, Sydney

Ocular Melanoma

11/24

11/25

ENZA-p, NCT04419402: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

Active, not recruiting

162

RoW

Lu-PSMA, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Enzalutamide, Xtandi

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Clinical Trials Centre, Prostate Cancer Research Alliance, Endocyte, Astellas Pharma Inc

Metastatic Castration-Resistant Prostate Cancer

07/24

01/25

UpFrontPSMA, NCT04343885: In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Active, not recruiting

130

RoW

177Lu-PSMA-617, 177Lu-PSMA-617 also referred to as 177Lu-PSMA, Docetaxel, Taxotere (trade name)

Peter MacCallum Cancer Centre, Australia, Movember Foundation, Prostate Cancer Research Alliance, United States Department of Defense, Advanced Accelerator Applications, Australia's Nuclear Science and Technology Organisation (ANSTO), Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australasian Radiopharmaceutical Trials network (ARTnet), Centre for Biostatistics and Clinical Trials (BaCT)

Metastatic Hormone Naive Prostate Cancer

04/24

SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated

205

Europe, US, RoW

ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda

Seagen Inc., Merck Sharp & Dohme LLC

Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma

11/23

EVOLUTION, NCT05150236: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

Active, not recruiting

RoW

177Lu-PSMA-617, 177Lutetium -PSMA 617 also referred to as 177Lu-PSMA, Ipilimumab, YERVOY, Nivolumab, OPDIVO

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Prostate Cancer Foundation of Australia, Bristol-Myers Squibb, Advanced Accelerator Applications, University of Sydney

Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Prostate Cancer, Neoplasms by Site, Neoplasms, Prostatic Disease

08/24

12/24

WOMBAT, NCT06594926: Working Out M0 Bipolar Androgen Therapy

Recruiting

RoW

Testosterone Enanthate, Primoteston Depot

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, The George Institute, HMRI

Prostate Cancer

12/26

12/28

HiTeCH, NCT03522064: Bipolar Androgen Therapy + Carboplatin in mCRPC

Recruiting

RoW

Testosterone Enanthate 100 MG/ML Injectable Solution, Primoteston Depot, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5

St Vincent's Hospital, Sydney

Castration-resistant Prostate Cancer, Homologous Recombination Deficiency

12/24

12/25

DECREASE, NCT04319783: Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Recruiting

RoW

Darolutamide, NUBEQA, Bayer HealthCare Pharmaceuticals Inc., Radiotherapy

Trans Tasman Radiation Oncology Group, Bayer, Peter MacCallum Cancer Centre, Australia

Advanced Prostate Carcinoma, Cancer of Prostate, PSA, Castrate Resistant Prostate Cancer

06/26

HITMAN, NCT03513211: Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

Completed

1/2

RoW

SUBA-itraconazole, Hydroxychloroquine

St Vincent's Hospital, Sydney

Prostate Cancer

08/23

10/23

TICTOC, NCT05156892: Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Recruiting

1/2

RoW

SUBA-itraconazole, Tamoxifen

Anthony Joshua, FRACP, Royal Prince Alfred Hospital, Sydney, Australia, Concord Hospital, Prince of Wales Hospital, Sydney, St Vincent's Hospital, Sydney

Ovarian Cancer

01/24

01/25

ENBolden-101, NCT04205227: ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

Active, not recruiting

1/2

137

US, RoW

ENB003, Pembrolizumab, KEYTRUDA®, MK-3475

ENB Therapeutics, Inc, Merck Sharp & Dohme LLC

Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor

01/26

03/26

LuPARP, NCT03874884: 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting

RoW

Olaparib, 177Lu-PSMA

Peter MacCallum Cancer Centre, Australia

Metastatic Castration Resistant Prostate Cancer (mCRPC)

05/25

06/26

NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Recruiting

120

US, RoW

IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab

InxMed (Shanghai) Co., Ltd.

Metastatic Melanoma

06/24

09/24

REPAIR, NCT05425862: Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Suspended

RoW

Pidnarulex, CX-5461, Talazoparib

Peter MacCallum Cancer Centre, Australia

Metastatic Castration Resistant Prostate Cancer (mCRPC)

07/24

12/25

OMNi, NCT04588662: A Prospective Natural History Study in Uveal Melanoma

Recruiting

N/A

700

Europe, Canada, US, RoW

Columbia University

Uveal Melanoma

07/26

IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting

N/A

5000

Europe, Canada, US, RoW

Standard of Care

Prostate Cancer Clinical Trials Consortium

Prostate Cancer

01/29



	Diseases Companies Products Productz Mechanisms of Action Sites